GlassScriptPhysician profile
Marcus L Williams
NPI 1467526525
$17,801.77
in general payments reported to CMS, 2019-2025
23 companies · $32.57 in 2025
The $32.57 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,827 · 2020: $1,683 · 2021: $5,754 · 2022: $659 · 2023: $272 · 2024: $1,573 · 2025: $32.57.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,200 · Food and Beverage: $667 · Education: $10.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,200.00 |
| Food and Beverage | $666.73 |
| Education | $10.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $14,157.85 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $1,249.60 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,075.40 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $262.91 | 2019-2022 | |
| Cvrx, INC. | $149.35 | 2024 | Barostim Neo System |
| Medtronic, INC. | $148.02 | 2023 | Corevalve Evolut R |
| Astrazeneca Pharmaceuticals LP | $120.29 | 2024 | Lokelma |
| Pfizer INC. | $99.90 | 2019-2024 | |
| Amarin Pharma, INC. | $78.66 | 2019-2021 | |
| Arbor Pharmaceuticals, INC. | $74.89 | 2019 | |
| Merck Sharp & Dohme LLC | $61.93 | 2021-2023 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $59.00 | 2019-2025 | Eliquis, Camzyos |
| Boston Scientific Corporation | $55.28 | 2020-2023 | Bodyguardian |
| Medline Industries LP | $47.80 | 2023-2024 | Medline Industries, INC. |
| Esperion Therapeutics, INC. | $47.61 | 2021-2024 | Nexletol |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $27.17 | 2019-2022 | |
| Scpharmaceuticals INC. | $21.67 | 2024 | |
| G Medical Diagnostic Services, INC. | $19.79 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $19.42 | 2023 | Opsumit |
| Lexicon Pharmaceuticals, INC. | $13.48 | 2023 | Inpefa |
| Regeneron Healthcare Solutions, INC. | $11.75 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcus Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.